RecruitingOverweightObesity

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Eligible age

18+ yrs

Accepts

All genders

Locations

21 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Are on stable incretin therapy at screening
✓ With persistent obesity or overweight defined as:
✓ ≥30 kg/m2 OR
✓ ≥27 kg/m2 with at least one existing obesity related complication at screening:
✓ hypertension
✓ dyslipidemia
✓ obstructive sleep apnea
✓ cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or

You may not qualify if…

✕ Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
✕ Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
✕ Have type 1 diabetes
✕ Have taken any of the following antihyperglycemic medications within 90 days before screening:
✕ dipeptidyl peptidase-4 (DPP-4) inhibitors
✕ amylin analogs
✕ insulin
✕ Have had within 90 days prior to screening: